Effect of tigecycline on coagulation markers: a retrospective study

Jing ZHANG; Rong ZHANG

doi:10.16016/j.1000-5404.201903027

您当前的位置：

首页 >

文章列表页 >

Effect of tigecycline on coagulation markers: a retrospective study

更新时间：2026-01-09

- Effect of tigecycline on coagulation markers: a retrospective study
- Journal of Third Military Medical University Vol. 41, Issue 15, Pages: 1485-1490(2019)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.16016/j.1000-5404.201903027
  CLC：
- Received：01 March 2019，
  
  Published：15 August 2019
- 稿件说明：
移动端阅览
Jing ZHANG, Rong ZHANG. Effect of tigecycline on coagulation markers: a retrospective study[J]. Journal of Third Military Medical University, 2019, 41(15): 1485-1490.
DOI：

Jing ZHANG, Rong ZHANG. Effect of tigecycline on coagulation markers: a retrospective study[J]. Journal of Third Military Medical University, 2019, 41(15): 1485-1490. DOI： 10.16016/j.1000-5404.201903027.

摘要

Abstract

Objective

To determine the effect of tigecyclin on coagulation markers in the patients taking it

and screen out the related risk factors.

Methods

A retrospective study was carried out on the patients with tigecycline treatment admitted to our hospital from January 2016 to December 2017 based on our hospital information system and the Meikang rational drug use monitoring system. Fibrinogen (FBG) level

prothrombin time (PT)

activated partial thromboplastin time (APTT)

thrombin time (TT)

platelet (PLT) count

glomerular filtration rate (eGFR)

and levels of alanine aminotransferase (ALT) and serum total bilirubin (TBIL) were compared before and after tigecycline administration. Finally

according to whether patients had abnormal coagulation indicators

Logistic regression was used to screen out high-risk factors of abnormal coagulation indexes caused by tigecycline.

Results

A total of 97 qualified cases were included in this study

including 69 males (71.1%) and 28 females (28.9%)

at a mean age of 56.93±19.31 years. Tigecycline treatment resulted in significantly decreased FBG level (

0.05) and prolonged PT

APTT and TT (

0.05)

but no such change was seen in PLT count. At the same time

there were no significant differences in ALT and TBIL levels before and after administration

and CRP and PCT showed significant differences (

0.05)

while WBC count showed no significant difference. The total WBC count

and CRP and PCT levels were decreased after administration

indicating the patients' infection status was improved. The eGFR value was remarkably improved (

0.05)

indicating better renal function. Logistic analysis showed that high dose of tigecycline was a risk factor for coagulopathy (

0.05

=3.96).

Conclusion

Tigecycline may cause decreased FBG

prolonged PT

APTT and TT

and the patients taking high dose tigecycline are prone to this adverse event.

关键词

Keywords

references

孙桂凤陈頔孙钊新一代抗菌药物替加环素的研究进展药品评价 2014 11 12 21 27 10.3969/j.issn.1672-2809.2014.12.004 孙桂凤, 陈頔, 孙钊, 等.新一代抗菌药物替加环素的研究进展[J].药品评价, 2014, 11(12):21-27. DOI:10.3969/j.issn.1672-2809.2014.12.004.

SUN G F CHEN D SUN Z Progress in the research of tigecycline, a new generation of antibacterials Drug Eva 2014 11 12 21 27 10.3969/j.issn.1672-2809.2014.12.004 SUN G F, CHEN D, SUN Z, et al . Progress in the research of tigecycline, a new generation of antibacterials[J ] . Drug Eva, 2014, 11(12):21-27.DOI:10.3969/j.issn.1672-2809.2014.12.004.

耐甲氧西林金黄色葡萄球菌感染防治专家委员会耐甲氧西林金黄色葡萄球菌感染防治专家共识2011年更新版中华实验和临床感染病杂志(电子版) 2011 5 3 66 72 http://d.old.wanfangdata.com.cn/Periodical/zhsyhlcgrbzz201103020 耐甲氧西林金黄色葡萄球菌感染防治专家委员会.耐甲氧西林金黄色葡萄球菌感染防治专家共识2011年更新版[J].中华实验和临床感染病杂志(电子版), 2011, 5(3):66-72.

Expert committee on the prevention and treatment of mrsa infection Expert consensus on the prevention and treatment of mrsa infection updated in 2011 Chin J Exp Clin Infect Dis(Electr Vers) 2011 5 3 66 72 http://d.old.wanfangdata.com.cn/Periodical/zhsyhlcgrbzz201103020 Expert committee on the prevention and treatment of mrsa infection. Expert consensus on the prevention and treatment of mrsa infection updated in 2011[J]. Chin J Exp Clin Infect Dis(Electr Vers), 2011, 5(3):66-72.

陈佰义何礼贤胡必杰中国鲍曼不动杆菌感染诊治与防控专家共识中华医学杂志 2012 92 2 76 85 10.3760/cma.j.issn.0376-2491.2012.02.002 陈佰义, 何礼贤, 胡必杰, 等.中国鲍曼不动杆菌感染诊治与防控专家共识[J].中华医学杂志, 2012, 92(2): 76- 85. DOI:10.3760/cma.j.issn.0376-2491.2012.02.002.

CHEN B Y HE L X HU B J Expert consensus on the diagnosis, treatment, prevention and control of acinetobacter baumannii infection National Med J China 2012 92 2 76 85 10.3760/cma.j.issn.0376-2491.2012.02.002 CHEN B Y, HE L X, HU B J, et al . Expert consensus on the diagnosis, treatment, prevention and control of acinetoba cter baumannii infection[J ] . National Med J China, 2012, 92(2): 76-85. DOI:10.3760/cma.j.issn.0376-2491.2012.02.002.

周华李光辉陈佰义中国产超广谱β-内酰胺酶肠杆菌科细菌感染应对策略专家共识中华医学杂志 2014 94 24 1847 1856 10.3760/cma.J.issn.0376-2491.2014.24.003 周华, 李光辉, 陈佰义, 等.中国产超广谱β-内酰胺酶肠杆菌科细菌感染应对策略专家共识[J].中华医学杂志, 2014, 94(24):1847-1856.DOI:10.3760/cma.J.issn.0376-2491.2014.24.003.

ZHOU H LI G H CHEN B Y Expert consensus on the strategy for the treatment of infection caused by enterobacteriaceae producing extented—spectrum betalactamases National Med J China 2014 94 24 1847 1856 10.3760/cma.J.issn.0376-2491.2014.24.003 ZHOU H, LI G H, CHEN B Y, et al . Expert consensus on the strategy for the treatment of infection caused by enterobacteriaceae producing extented—spectrum betalactamases[J ] . National Med J China, 2014, 94(24): 1847-1856.DOI:10.3760/cma.J.issn.0376-2491.2014.24.003.

GIRYES S AZZAM Z S ISMAEL-BADARNEH R Severe coagulation disorder and thrombocytopenia associated with tigecycline-case report and review of literature Curr Drug Saf 2017 12 1 7 9 10.2174/1574886311666160920090714 GIRYES S, AZZAM Z S, ISMAEL-BADARNEH R, et al . Severe coagulation disorder and thrombocytopenia associated with tigecycline-case report and review of literature[J ] . Curr Drug Saf, 2017, 12(1): 7-9. DOI:10.2174/157488 6311666160920090714.

PIERINGER H SCHMEKAL B BIESENBACH G Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline Ann Hematol 2010 89 10 1063 1064 10.1007/s00277-010-0911-7 PIERINGER H, SCHMEKAL B, BIESENBACH G, et al . Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline[J ] . Ann Hematol, 2010, 89(10):1063-1064.DOI:10.1007/s00277-010-0911-7.

ROSSITTO G PIANO S ROSI S Life-threatening coagulopathy and hypofibrinogenaemia induced by tigecycline in a patient with advanced liver cirrhosis Eur J Gastroenterol Hepatol 2014 26 6 681 684 10.1097/MEG.0000000000000087 ROSSITTO G, PIANO S, ROSI S, et al . Life-threatening coagulopathy and hypofibrinogenaemia induced by tigecycline in a patient with advanced liver cirrhosis[J ] . Eur J Gastroenterol Hepatol, 2014, 26(6):681-684. DOI:10.1097/MEG.0000000000000087.

SABANIS N PASCHOU E GAVRⅡLAKI E Hypofibrinogenemia induced by tigecycline: A potentially life-threatening coagulation disorder Infect Dis (Lond) 2015 47 10 743 746 10.3109/23744235.2015.1043942 SABANIS N, PASCHOU E, GAVRⅡLAKI E, et al . Hypofibrinogenemia induced by tigecycline: A potentially life-threatening coagulation disorder[J ] . Infect Dis (Lond), 2015, 47(10):743-746.DOI:10.3109/23744235.2015.1043942.

ZHANG Q ZHOU S M ZHOU J Tigecycline treatment causes a decrease in fibrinogen levels Antimicrob Agents Chemother 2015 59 3 1650 1655 10.1128/AAC.04305-14 ZHANG Q, ZHOU S M, ZHOU J. Tigecycline treatment causes a decrease in fibrinogen levels[J]. Antimicrob Agents Chemother, 2015, 59(3):1650-1655.DOI:10.1128/AAC.04305-14.

尚红王毓三申子瑜全国临床检验操作规程 4版北京人民卫生出版社 2015 尚红, 王毓三, 申子瑜.全国临床检验操作规程[M]. 4版.北京:人民卫生出版社, 2015.

SHANG H WANG Y S SHEN Z Y National guide to clinical laboratory procedures 4th Edition Beijing People's Medical Publishing House 2015 SHANG H, WANG Y S, SHEN Z Y. National guide to clinical laboratory procedures[M]. 4th Edition. Beijing: People's Medical Publishing House, 2015.

刘春亮王华替加环素的研究进展及临床应用安徽医药 2007 11 7 648 650 10.3969/j.issn.1009-6469.2007.07.045 刘春亮, 王华.替加环素的研究进展及临床应用[J].安徽医药, 2007, 11(7): 648-650. DOI:10.3969/j.issn.1009-6469.2007.07.045.

LIU C L WANG H Research progress and clinical application of tigecycline Anhui Med Pharmaceutical J 2007 11 7 648 650 10.3969/j.issn.1009-6469.2007.07.045 LIU C L, WANG H. Research progress and clinical application of tigecycline[J]. Anhui Med Pharmaceutical J, 2007, 11(7):648-650.DOI:10.3969/j.issn.1009-6469.2007.07.045.

程仕虎王睿新一代四环素类药物替加环素的研究进展科学技术与工程 2007 7 16 4123 4130 10.3969/j.issn.1671-1815.2007.16.033 程仕虎, 王睿.新一代四环素类药物替加环素的研究进展[J].科学技术与工程, 2007, 7(16): 4123-4130. DOI:10.3969/j.issn.1671-1815.2007.16.033.

CHENG S H WANG R Research development of tigecycline: A new glycylcycline antimicrobial agent Sci Tech Engineering 2007 7 16 4123 4130 10.3969/j.issn.1671-1815.2007.16.033 CHENG S H, WANG R. Research development of tigecycline: A new glycylcycline antimicrobial agent[J]. Sci Tech Engineering, 2007, 7(16):4123-4130.DOI:10.3969/j.issn.1671-1815.2007.16.033.

蒋春晖替加环素抗耐药菌作用的研究进展中国药房 2012 23 42 4013 4015 10.6039/j.issn.1001-0408.2012.42.30 蒋春晖.替加环素抗耐药菌作用的研究进展[J].中国药房, 2012, 23(42): 4013-4015.

JIANG C H Advances in research on the effects of tigecycline on resistant bacteria China Pharmacy 2012 23 42 4013 4015 10.6039/j.issn.1001-0408.2012.42.30 JIANG C H. Advances in research on the effects of tigecycline on resistant bacteria[J]. China Pharmacy, 2012, 23(42): 4013-4015.

钟雪陈东科许宏涛替加环素研究新进展中国抗生素杂志 2015 40 11 870 875 10.3969/j.issn.1001-8689.2015.11.015 钟雪, 陈东科, 许宏涛, 等.替加环素研究新进展[J].中国抗生素杂志, 2015, 40(11): 870-875. DOI:10.3969/j.issn.1001-8689.2015.11.015.

ZHONG X CHEN D K XU H T New advance in the study of tigecycline Chin J Antibiotics 2015 40 11 870 875 10.3969/j.issn.1001-8689.2015.11.015 ZHONG X, CHEN D K, XU H T, et al . New advance in the study of tigecycline[J ] . Chin J Antibiotics, 2015, 40(11): 870-875. DOI:10.3969/j.issn.1001-8689.2015.11.015.

MURALIDHARAN G MICALIZZI M SPETH J Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects Antimicrob Agents Chemother 2005 49 1 220 229 10.1128/AAC.49.1.220-229.2005 MURALIDHARAN G, MICALIZZI M, SPETH J, et al . Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects[J ] . Antimicrob Agents Chemother, 2005, 49(1):220-229.DOI:10.1128/AAC.49.1.220-229.2005.

薛峰 . 替加环素对患者凝血功能影响的临床回顾分析 [D ] . 济南 : 山东大学 , 2016 . http://cdmd.cnki.com.cn/Article/CDMD-10422-1016203903.htm 薛峰.替加环素对患者凝血功能影响的临床回顾分析[D].济南: 山东大学, 2016. http://cdmd.cnki.com.cn/Article/CDMD-10422-1016203903.htm

XUE F . Clinical retrospective analysis of tigecycline treatment effect on patients' coagulation function [D ] . Jinan : Shandong University , 2016 . XUE F. Clinical retrospective analysis of tigecycline treatment effect on patients' coagulation function[D]. Jinan: Shandong University, 2016.

ELLIS-GROSSE E J BABINCHAK T DARTOIS N The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam Clin Infect Dis 2005 41 Suppl 5 S341 S353 10.1086/431675 ELLIS-GROSSE E J, BABINCHAK T, DARTOIS N, et al . The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam[J ] . Clin Infect Dis, 2005, 41(Suppl 5): S341-S353. DOI:10.1086/431675.

LEVI M The coagulant response in sepsis and inflammation Hamostaseologie 2010 30 1 10 6 10-12, 14-6 10.1055/s-0037-1617143 LEVI M. The coagulant response in sepsis and inflammation[J]. Hamostaseologie, 2010, 30(1): 10-12, 14-6.

肖昌钱韩奇替加环素致血小板减少2例医药导报 2018 37 1 125 127 10.3870/j.issn.1004-0781 肖昌钱, 韩奇.替加环素致血小板减少2例[J].医药导报, 2018, 37(1): 125-127. DOI:10.3870/j.issn.1004-0781.

XIAO C Q HAN Q 2 cases of thrombocytopenia caused by tigecycline Herald Med 2018 37 1 125 127 10.3870/j.issn.1004-0781 XIAO C Q, HAN Q. 2 cases of thrombocytopenia caused by tigecycline[J]. Herald Med, 2018, 37(1): 125-127. DOI:10.3870/j.issn.1004-0781.

潘虹董亮张秀红替加环素致1例凝血功能障碍药学与临床研究 2018 26 3 233 234 10.13664/j.cnki.pcr.2018.03.022 潘虹, 董亮, 张秀红.替加环素致1例凝血功能障碍[J].药学与临床研究, 2018, 26(3): 233-234. DOI:10.13664/j.cnki.pcr.2018.03.022.

PAN H DONG L ZHANG X H One case of coagulation dysfunction caused by tigecycline Pharmaceutical Clin Res 2018 26 3 233 234 10.13664/j.cnki.pcr.2018.03.022 PAN H, DONG L, ZHANG X H. One case of coagulation dysfunction caused by tigecycline[J]. Pharmaceutical Clin Res, 2018, 26(3):233-234.DOI:10.13664/j.cnki.pcr.2018.03.022.

WU X Q ZHAO P DONG L A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia Med (Baltimore) 2017 96 49 e9124 10.1097/MD.0000000000009124 WU X Q, ZHAO P, DONG L, et al . A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia[J ] . Med (Baltimore), 2017, 96(49):e9124.DOI:10.1097/MD.0000000000009124.

WU P C WU C C Tigecycline-associated hypofibrinogenemia: A case report and review of the literature IDCases 2018 11 56 57 10.1016/j.idcr.2018.01.003 WU P C, WU C C. Tigecycline-associated hypofibrinogenemia: A case report and review of the literature[J]. IDCases, 2018, 11: 56-57. DOI:10.1016/j.idcr.2018.01.003.

黄梅娟薛加玲于维松替加环素相关凝血功能障碍文献概述中国药师 2017 20 11 2046 2048, 2095 10.3969/j.issn.1008-049X.2017.11.042 黄梅娟, 薛加玲, 于维松.替加环素相关凝血功能障碍文献概述[J].中国药师, 2017, 20(11): 2046-2048, 2095.

HUANG M J XUE J L YU W S Summary of the literatures on coagulation disorders associated with tigecyclin China Pharmacist 2017 20 11 2046 2048, 2095 10.3969/j.issn.1008-049X.2017.11.042 HUANG M J, XUE J L, YU W S. Summary of the literatures on coagulation disorders associated with tigecyclin[J]. China Pharmacist, 2017, 20(11): 2046-2048, 2095.

FISH R J NEERMAN-ARBEZ M Fibrinogen gene regulation Thromb Haemost 2012 108 3 419 426 10.1160/TH12-04-0273 FISH R J, NEERMAN-ARBEZ M. Fibrinogen gene regulation[J]. Thromb Haemost, 2012, 108(3): 419-426. DOI:10.1160/TH12-04-0273.

WANG H J DENG J WANG J Y Serum miR-122 levels are related to coagulation disorders in sepsis patients Clin Chem Lab Med 2014 52 6 927 933 10.1515/cclm-2013-0899 WANG H J, DENG J, WANG J Y, et al . Serum miR-122 levels are related to coagulation disorders in sepsis patients[J ] . Clin Chem Lab Med, 2014, 52(6): 927-933. DOI:10.1515/cclm-2013-0899.

ROUTSI C KOKKORIS S DOUKA E High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections Int J Antimicrob Agents 2015 45 1 90 93 10.1016/j.ijantimicag.2014.07.014 ROUTSI C, KOKKORIS S, DOUKA E, et al . High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections[J ] . Int J Antimicrob Agents, 2015, 45(1):90-93. DOI:10.1016/j.ijantimicag.2014.07.014.

MCMAHAN J MOENSTER R P Tigecycline-induced coagulopathy AJHP 2017 74 3 130 134 10.2146/ajhp150894 MCMAHAN J, MOENSTER R P. Tigecycline-induced coagulopathy[J]. AJHP, 2017, 74(3): 130-134. doi:10.2146/ajhp150894.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Role and mechanism of tigecycline in delaying the resistance of Klebsiella pneumoniae to polymyxin B by inhibiting cpxR

Features of early injuries in canine model of high dose depleted uranium exposure through bronchial spraying

Application value of combined detection of D-dimer and fibrinogen in diagnosis of deep venous thrombosis

Serum levels of high mobility group box-1 and interleukin-6 in cerebral infarction patients and their correlation with the disease’s risk factors

Related Author

FENG Wei

HUA Shangjun

QIAN Yan

ZHANG Huanhuan

刘明华

肖瑶

曾峰

田铸

Related Institution

Department of Pharmacy， the Second Affiliated Hospital of Chongqing Medical University

Department of Pharmacy， First Affiliated Hospital， Army Medical University （Third Military Medical University）

⁰